The Medicines Company acquires cangrelor from AstraZeneca
Executive Summary
The Medicines Company acquires antiplatelet agent cangrelor from AstraZeneca. The short-acting, intravenous non-thienopyridine compound is in Phase II and requires manufacturing work over the next 12-18 months, The Medicines Company says. The company expects to start Phase III trials in 2005...